Investor Relations

Castlight Health Announces Third Quarter 2019 Results
10/24/2019
Signs Anthem, Inc. to Enterprise License Agreement
Launches Personalized High-Touch Offering for Health Navigation Platform Customers
Expands Leadership Team

SAN FRANCISCO, Oct. 24, 2019 /PRNewswire/ -- Castlight Health, Inc. (NYSE:CSLT), a leading health benefits platform provider, today announced results for its third quarter ended September 30, 2019.

Castlight Logo (PRNewsfoto/Castlight Health)

Recent Highlights

  • Signed Anthem, Inc. to a 30-month enterprise license agreement, effective January 1, 2020, which renews the Engage relationship and provides a non-exclusive license for components of Castlight's core platform services
  • Launched its new personalized high-touch solution, Castlight Care Guides, and announced a Charter Customer Program that includes a Fortune 500 customer
  • Selected its new Customer Center of Excellence in Salt Lake City, Utah, and hired and trained its inaugural class of Castlight employees
  • Announced the following senior management appointments:
    • Helen Kotchoubey hired as executive vice president and chief operating officer
    • Will Bondurant promoted to senior vice president and chief financial officer, effective November 15, 2019
    • Matt Moran hired as senior vice president of corporate development to lead health plan and new growth initiatives

"We've made significant progress on our top priorities over the last ninety days. Our new Anthem enterprise license agreement is meaningful validation of our technology and a proof point for our growth strategy," said Maeve O'Meara, chief executive officer of Castlight Health. "In addition to expanding our Anthem relationship, Castlight made meaningful advances in jump-starting our health plan growth initiative, reinvigorating our customer base with value-based innovation, and assembling a strong team to lead Castlight in its next chapter. These steps are foundational to our long-term success."

For more information on the Anthem enterprise license agreement, please see the associated 8-K filing with the Securities and Exchange Commission and the press release entitled "Anthem, Inc. Signs Enterprise Licensing Agreement with Castlight Health" dated October 24, 2019. Also, please see the press release entitled "Castlight Health Announces Castlight Care Guides" dated October 22, 2019 for more information on the Castlight Care Guides announcement.

Financial performance for the three months ended September 30, 2019 compared to the three months ended September 30, 2018 includes:

  • GAAP total revenue of $35.5 million, representing a decrease of 11.4%
  • GAAP gross margin of 59.1%, compared to 63.1%
  • Non-GAAP gross margin of 62.1%, compared to 67.7%
  • GAAP operating loss of $9.6 million, compared to $7.5 million
  • Non-GAAP operating loss of $5.4 million, compared to income of $0.3 million
  • GAAP net loss per basic and diluted share of $0.06, compared to a net loss per basic and diluted share of $0.05
  • Non-GAAP net loss per basic and diluted share of $0.04, compared to a net income per basic and diluted share of $0.00
  • Cash used in operations of $7.4 million, compared to $6.0 million

Total cash, cash equivalents and marketable securities was $56.0 million as of September 30, 2019.

A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."

Business Outlook

For the full year 2019, the Company expects:

  • GAAP revenue in line with its previously-issued range of $140 million to $145 million
  • Non-GAAP operating loss to exceed $13 million, the high-end of its previously-issued range of $8 million to $13 million
  • Non-GAAP net loss per share to exceed $0.09, the high-end of its previously-issued range of $0.06 to $0.09 based on approximately 145 million to 146 million shares

About Helen Kotchoubey

Helen is an experienced healthcare operations leader and advisor. From 2017 to August 2018, Helen served as chief of staff at New York-Presbyterian Brooklyn Methodist Hospital where she integrated $1 billion in hospital assets into a nationally recognized academic healthcare delivery system and oversaw a 300-person staff across sixteen departments. From 2006 to 2017, Helen held multiple operating roles at New York-Presbyterian Hospital including vice president of IT strategy where she led financial and strategic planning initiatives and managed the department's annual operating budget. Prior to that, Helen served as director of revenue cycle management at Montefiore Medical Center in New York and as a manager and consultant at Deloitte in their healthcare practice. Helen holds an MBA from Harvard Business School and a BA from Amherst College.

About Will Bondurant

Will Bondurant is a six-year veteran of Castlight Health with deep operational experience across the Company's finance, product, and customer-facing functions, including serving as the lead of Castlight's Anthem relationship since 2017. Will began his Castlight career in 2013 as director, strategy and corporate development where he led the annual and corporate planning and strategy processes. In 2015, Will served as director, product marketing where he was responsible for product positioning, pricing and market strategy. In 2017, Will served as senior director, health plan strategy where he negotiated and launched Castlight's partnership with Anthem and the distribution of the Engage health navigation app. In 2018, Will served as vice president, professional services where he was responsible for client launches and migrations. Prior to joining Castlight, Will served as an analyst at McKinsey & Company focusing on healthcare delivery. Will holds a BA from the University of North Carolina.

About Matt Moran

Matt is a proven leader in digital health and has been working in healthcare since 2002. From 2015 to September 2019, Matt worked at Rally Health, most recently as vice president of strategy. From 2006 to 2015, Matt was at Prime Therapeutics, a pharmacy benefit manager serving 22 Blues plans and 28 million members. From 2013 to 2015, Matt served as Prime's vice president of client engagement where he was responsible for the strategic alignment, sales, and business performance between the company and its Blue Cross Blue Shield health plan partners. Before joining Prime, Matt held positions in Deloitte Consulting's healthcare and life sciences practice and at Health Care Services Corporation (Blue Cross Blue Shield) in Chicago. Matt holds an MBA from the University of Notre Dame and a BBA from Indiana University.

Quarterly Conference Call

Castlight Health senior management will host a conference call to discuss its third quarter 2019 results and business outlook today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast of the conference call, together with detailed financial information, can be accessed through the Company's Investor Relations website at http://ir.castlighthealth.com. An archive of the webcast can also be accessed through the same link. The live conference call can be accessed by dialing (833) 238-7953 and the replay will be available for one week at (800) 585-8367.  The conference ID number for the live call and replay is 5829129.

About Castlight Health

Castlight is on a mission to make it as easy as humanly possible to navigate healthcare and live happier, healthier, more productive lives. Our health navigation platform connects with hundreds of health vendors, benefits resources, and plan designs, giving rise to the world's first comprehensive app for all health needs. We guide individuals-based on their unique profile- to the best resources available to them, whether they are healthy, chronically ill, or actively seeking medical care. In doing so, we help companies regain control over rising healthcare costs and get more value from their benefits investments. Castlight revolutionized the healthcare sector with the introduction of data-driven price transparency tools in 2008 and the first consumer-grade wellbeing platform in 2012. Today, Castlight serves as the health navigation platform for millions of people and is a trusted partner to many of the largest employers in the world.

For more information visit www.castlighthealth.com. Follow us on Twitter and LinkedIn and Like us on Facebook.

Non-GAAP Financial Measures

To supplement Castlight Health's financial statements presented in accordance with generally accepted accounting principles (GAAP), we also use and provide investors and others with non-GAAP measures of certain components of financial performance, including non-GAAP gross profit and margin, non-GAAP operating expense, non-GAAP operating income (loss), non-GAAP net income (loss) and non-GAAP net income (loss) per share. Non-GAAP gross profit and margin, non-GAAP operating expense, non-GAAP operating income (loss), and non-GAAP net income (loss) exclude stock-based compensation, certain legal expenses, amortization of intangibles, restructuring charges, amortization of internal-use software, and lease exit and related charges.

We believe that these non-GAAP financial measures provide useful supplemental information to investors and others, facilitate the analysis of the company's core operating results and comparison of operating results across reporting periods, and can help enhance overall understanding of the company's historical financial performance.

We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, except that we have not reconciled our non-GAAP operating loss and net loss per share guidance for the full year 2019 to comparable GAAP measures because we do not provide guidance for stock-based compensation expense, and capitalization and amortization of internal-use software, which are reconciling items between GAAP and non-GAAP. The factors that may impact our future stock-based compensation expense, and capitalization and amortization of internal-use software are out of our control and/or cannot be reasonably predicted, and therefore we are unable to provide such guidance without unreasonable effort. Factors include our market capitalization and related volatility of our stock price and our inability to project the cost or scope of internally produced software.

These non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, measures prepared in accordance with GAAP.

Further, these non-GAAP measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore comparability may be limited. Castlight Health encourages investors and others to review the company's financial information in its entirety and not rely on a single financial measure.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements about Castlight Health's expectations, plans, intentions, and strategies, including, but not limited to, statements regarding Castlight Health's third quarter performance and 2019 full year projections, executive leadership, the success of our strategy and our expectations for our future business and financial performance. Statements including words such as "anticipate," "believe," "estimate," "will," "continue," "expect," or "future," and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in Castlight Health's documents filed with or furnished to the Securities and Exchange Commission, including the risks set forth in our quarterly report on Form 10-Q for the three months ended September 30, 2019. All forward-looking statements in this press release are based on information available to Castlight Health as of the date hereof. Castlight Health assumes no obligation to update these forward-looking statements.

Copyright 2019 Castlight Health, Inc. Castlight Health® is the registered trademark of Castlight Health, Inc. Other company and product names may be trademarks of the respective companies with which they are associated.

 

CASTLIGHT HEALTH, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(unaudited)



As of


September 30, 2019


December 31, 2018

Assets




Current assets:




Cash and cash equivalents

$

36,040


$

66,005

Marketable securities

19,977


11,327

Accounts receivable and other, net

35,442


26,816

Prepaid expenses and other current assets

4,512


3,680

Total current assets

95,971


107,828

Property and equipment, net

3,318


3,963

Restricted cash, non-current

1,325


1,325

Deferred commissions

17,242


20,142

Deferred professional service costs

8,429


10,133

Intangible assets, net

13,253


16,209

Goodwill

91,785


91,785

Operating lease right-of-use assets, net

13,351


Other assets

2,119


2,129

Total assets

$

246,793


$

253,514

Liabilities and stockholders' equity




Current liabilities:




Accounts payable

$

11,989


$

9,556

Accrued expenses and other current liabilities

11,169


15,454

Accrued compensation

5,547


5,975

Deferred revenue

17,509


20,193

Operating lease liabilities

5,897


Total current liabilities

52,111


51,178

Deferred revenue, non-current

824


1,030

Debt, non-current

1,860


3,254

Operating lease liabilities, non-current

10,574


Other liabilities, non-current

1,125


3,381

Total liabilities

66,494


58,843

Stockholders' equity

180,299


194,671

Total liabilities and stockholders' equity

$

246,793


$

253,514

 

CASTLIGHT HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(unaudited)



Three Months Ended September 30,


Nine Months Ended September 30,


2019


2018


2019


2018

Revenue:








Subscription

$

34,900


$

36,702


$

102,670


$

104,493

Professional services and other

561


3,339


4,191


9,811

Total revenue, net

35,461


40,041


106,861


114,304

Cost of revenue:








Cost of subscription(1)

8,517


8,558


24,917


26,872

Cost of professional services and other(1)

5,984


6,237


17,857


18,596

Total cost of revenue

14,501


14,795


42,774


45,468

Gross profit

20,960


25,246


64,087


68,836

Operating expenses:








Sales and marketing(1)

9,829


11,497


27,933


38,715

Research and development(1)

14,295


15,028


44,507


46,824

General and administrative(1)

6,440


6,193


20,743


19,400

Total operating expenses

30,564


32,718


93,183


104,939

Operating loss

(9,604)


(7,472)


(29,096)


(36,103)

Other income, net

268


207


840


436

Net loss

$

(9,336)


$

(7,265)


$

(28,256)


$

(35,667)

Net loss per share, basic and diluted

$

(0.06)


$

(0.05)


$

(0.20)


$

(0.26)

Weighted-average shares used to compute basic and diluted net loss per share

145,701


138,490


144,434


136,735


     (1)  Includes stock-based compensation expense as follows:




Three Months Ended September 30,


Nine Months Ended September 30,


2019


2018


2019


2018

Cost of revenue:








Cost of subscription

$

180


$

322


$

595


$

795

Cost of professional services and other

236


322


737


938

Sales and marketing

678


699


1,967


3,155

Research and development

1,294


1,798


4,731


5,360

General and administrative

625


1,129


3,817


3,761













 

CASTLIGHT HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(unaudited)



Three Months Ended September 30,


Nine Months Ended September 30,


2019


2018


2019


2018

Operating activities:








Net loss

$

(9,336)


$

(7,265)


$

(28,256)


$

(35,667)

Adjustments to reconcile net loss to net cash used in operating activities:








Depreciation and amortization

1,681


1,698


4,368


5,271

Stock-based compensation

3,013


4,270


11,847


14,009

Amortization of deferred commissions

2,547


3,217


7,403


9,017

Amortization of deferred professional service costs

1,096


1,254


3,110


3,351

Non-cash operating lease expense

1,339



3,919


Lease exit and related charges


253



2,070

Accretion and amortization of marketable securities

(30)


(126)


(243)


(392)

Changes in operating assets and liabilities:








Accounts receivable and other, net

(2,831)


(2,050)


(8,626)


(8,302)

Deferred commissions

(1,833)


(2,201)


(4,503)


(5,180)

Deferred professional service costs

(400)


(721)


(1,301)


(2,110)

Prepaid expenses and other assets

1,042


777


(822)


(1,119)

Accounts payable

513


1,234


2,377


1,745

Operating lease liabilities

(1,472)



(4,267)


Accrued expenses and other liabilities

59


(1,537)


(3,072)


1,645

Deferred revenue

(3,202)


(1,105)


(2,890)


(2,315)

Accrued compensation

378


(3,669)


(428)


(8,080)

Net cash used in operating activities

(7,436)


(5,971)


(21,384)


(26,057)

Investing activities:








Purchase of property and equipment

(119)


(591)


(712)


(1,895)

Purchase of marketable securities

(9,289)


(1,451)


(23,069)


(25,430)

Maturities of marketable securities

3,217


9,900


14,670


36,350

Net cash (used in) provided by investing activities

(6,191)


7,858


(9,111)


9,025

Financing activities:








Proceeds from exercise of stock options

79


371


1,924


2,613

Principal payments on long-term debt

(464)



(1,394)


Net cash (used in) provided by financing activities

(385)


371


530


2,613









Net (decrease) increase in cash, cash equivalents and restricted cash

(14,012)


2,258


(29,965)


(14,419)

Cash, cash equivalents and restricted cash at beginning of period

51,377


45,967


67,330


62,644

Cash, cash equivalents and restricted cash at end of period

$

37,365


$

48,225


$

37,365


$

48,225









Reconciliation of cash, cash equivalents and restricted cash:








Cash and cash equivalents

$

36,040


$

46,900


$

36,040


$

46,900

Restricted cash

1,325


1,325


1,325


1,325

Total cash, cash equivalents and restricted cash

$

37,365


$

48,225


$

37,365


$

48,225


 

CASTLIGHT HEALTH, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(In thousands, except per share data)
(unaudited)



Three Months Ended


Nine Months Ended


September 30,
2019


June 30, 2019


September 30,
2018


September 30,
2019


September 30,
2018

Gross profit:










GAAP gross profit subscription

$

26,383


$

25,730


$

28,144


$

77,753


$

77,621

Stock-based compensation

180


196


322


595


795

Amortization of internal-use software



220



658

Amortization of intangibles

660


587


678


1,834


2,034

Reduction in workforce



130



130

Non-GAAP gross profit subscription

$

27,223


$

26,513


$

29,494


$

80,182


$

81,238

GAAP gross margin subscription

75.6

%


75.8

%


76.7

%


75.7

%


74.3

%

Non-GAAP gross margin subscription

78.0

%


78.1

%


80.4

%


78.1

%


77.7

%











GAAP gross loss professional services

$

(5,423)


$

(3,983)


$

(2,898)


$

(13,666)


$

(8,785)

Stock-based compensation

236


236


322


737


938

Reduction in workforce



173



173

Non-GAAP gross loss professional services

$

(5,187)


$

(3,747)


$

(2,403)


$

(12,929)


$

(7,674)

GAAP gross margin professional services

(967)

%


(205)

%


(86.8)

%


(326)

%


(89.5)

%

Non-GAAP gross margin professional services

(925)

%


(193)

%


(72.0)

%


(308)

%


(78.2)

%











GAAP gross profit

$

20,960


$

21,747


$

25,246


$

64,087


$

68,836

Impact of non-GAAP adjustments

1,076


1,019


1,845


3,166


4,728

Non-GAAP gross profit

$

22,036


$

22,766


$

27,091


$

67,253


$

73,564

GAAP gross margin

59.1

%


60.6

%


63.1

%


60.0

%


60.2

%

Non-GAAP gross margin

62.1

%


63.4

%


67.7

%


62.9

%


64.4

%











Operating expense:










GAAP sales and marketing

$

9,829


$

8,889


$

11,497


$

27,933


$

38,715

Stock-based compensation

(678)


(662)


(699)


(1,967)


(3,155)

Amortization of intangibles

(528)


(272)


(271)


(1,072)


(992)

Reduction in workforce



(1,055)



(1,055)

Non-GAAP sales and marketing

$

8,623


$

7,955


$

9,472


$

24,894


$

33,513











GAAP research and development

$

14,295


$

14,487


$

15,028


$

44,507


$

46,824

Stock-based compensation

(1,294)


(1,733)


(1,798)


(4,731)


(5,360)

Reduction in workforce



(522)



(522)

Certain legal expenses




(191)


Lease exit and related charges



(253)



(2,011)

Non-GAAP research and development

$

13,001


$

12,754


$

12,455


$

39,585


$

38,931











GAAP general and administrative

$

6,440


$

7,010


$

6,193


$

20,743


$

19,400

Stock-based compensation

(625)


(2,030)


(1,129)


(3,817)


(3,761)

Amortization of intangibles

(16)


(17)


(16)


(50)


(50)

Certain legal expenses




(533)


Reduction in workforce



(172)



(172)

Non-GAAP general and administrative

$

5,799


$

4,963


$

4,876


$

16,343


$

15,417











GAAP operating expense

$

30,564


$

30,386


$

32,718


$

93,183


$

104,939

Impact of non-GAAP adjustments

(3,141)


(4,714)


(5,915)


(12,361)


(17,078)

Non-GAAP operating expense

$

27,423


$

25,672


$

26,803


$

80,822


$

87,861











Operating loss:










GAAP operating loss

$

(9,604)


$

(8,639)


$

(7,472)


$

(29,096)


$

(36,103)

Impact of non-GAAP adjustments

4,217


5,733


7,760


15,527


21,806

Non-GAAP operating loss (income)

$

(5,387)


$

(2,906)


$

288


$

(13,569)


$

(14,297)











Net (loss) income and net (loss) income per share:










GAAP net loss

$

(9,336)


$

(8,381)


$

(7,265)


$

(28,256)


$

(35,667)

Total pre-tax impact of non-GAAP adjustments

4,217


5,733


7,760


15,527


21,806

Non-GAAP net (loss) income

$

(5,119)


$

(2,648)


$

495


$

(12,729)


$

(13,861)

GAAP net loss per share, basic and diluted

$

(0.06)


$

(0.06)


$

(0.05)


$

(0.20)


$

(0.26)

Non-GAAP net (loss) income per share, basic and diluted

$

(0.04)


$

(0.02)


$

0.00


$

(0.09)


$

(0.10)

Shares used in basic and diluted net (loss) income per share computation

145,701


144,572


138,490


144,434


136,735





















 

Castlight Media Contact:
Courtney Lamie
press@castlighthealth.com
276-492-4248

Castlight Investor Contact:
Gary J. Fuges, CFA
ir@castlighthealth.com
415-829-1680

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/castlight-health-announces-third-quarter-2019-results-300945169.html

SOURCE Castlight Health, Inc.

Contact Investor Relations

Email Alerts